Stockreport

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma [Yahoo! Finance]

CureVac N.V. - Ordinary Shares  (CVAC) 
PDF Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSW [Read more]